Overview

A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors

Status:
RECRUITING

Trial end date:
2029-06-19

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary clinical activity of RO7567132 as single agent and in combination with atezolizumab. The study will enroll adult participants with selected locally advanced and/or metastatic solid tumors for whom standard therapy does not exist, or has proven to be ineffective or intolerable.

Phase:

PHASE1

Details

Lead Sponsor:

Hoffmann-La Roche

Treatments:

atezolizumab